These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 16600214)

  • 41. Cytological properties of stromal cells derived from giant cell tumor of bone (GCTSC) which can induce osteoclast formation of human blood monocytes without cell to cell contact.
    Nishimura M; Yuasa K; Mori K; Miyamoto N; Ito M; Tsurudome M; Nishio M; Kawano M; Komada H; Uchida A; Ito Y
    J Orthop Res; 2005 Sep; 23(5):979-87. PubMed ID: 16024207
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A p38alpha selective mitogen-activated protein kinase inhibitor prevents periodontal bone loss.
    Kirkwood KL; Li F; Rogers JE; Otremba J; Coatney DD; Kreider JM; D'Silva NJ; Chakravarty S; Dugar S; Higgins LS; Protter AA; Medicherla S
    J Pharmacol Exp Ther; 2007 Jan; 320(1):56-63. PubMed ID: 17041006
    [TBL] [Abstract][Full Text] [Related]  

  • 43. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
    Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pathogenesis of myeloma bone disease.
    Roodman GD
    Blood Cells Mol Dis; 2004; 32(2):290-2. PubMed ID: 15003820
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF.
    Knowles HJ; Athanasou NA
    J Pathol; 2008 May; 215(1):56-66. PubMed ID: 18283716
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tumor necrosis factor-alpha up-regulates the expression of CCL2 and adhesion molecules of human proximal tubular epithelial cells through MAPK signaling pathways.
    Ho AW; Wong CK; Lam CW
    Immunobiology; 2008; 213(7):533-44. PubMed ID: 18656701
    [TBL] [Abstract][Full Text] [Related]  

  • 47. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis.
    Edwards JR; Sun SG; Locklin R; Shipman CM; Adamopoulos IE; Athanasou NA; Sabokbar A
    Arthritis Rheum; 2006 May; 54(5):1451-62. PubMed ID: 16649193
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.
    Giuliani N; Colla S; Sala R; Moroni M; Lazzaretti M; La Monica S; Bonomini S; Hojden M; Sammarelli G; Barillè S; Bataille R; Rizzoli V
    Blood; 2002 Dec; 100(13):4615-21. PubMed ID: 12393684
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting.
    Cassinelli G; Ronchetti D; Laccabue D; Mattioli M; Cuccuru G; Favini E; Nicolini V; Greco A; Neri A; Zunino F; Lanzi C
    Biochem Pharmacol; 2009 Nov; 78(9):1139-47. PubMed ID: 19555670
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of human marrow stromal cells on activation of microglial cells and production of inflammatory factors induced by lipopolysaccharide.
    Zhou C; Zhang C; Chi S; Xu Y; Teng J; Wang H; Song Y; Zhao R
    Brain Res; 2009 May; 1269():23-30. PubMed ID: 19269277
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antimyeloma effects of a sesquiterpene lactone parthenolide.
    Suvannasankha A; Crean CD; Shanmugam R; Farag SS; Abonour R; Boswell HS; Nakshatri H
    Clin Cancer Res; 2008 Mar; 14(6):1814-22. PubMed ID: 18347184
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Osteocyte apoptosis regulates osteoclast precursor adhesion via osteocytic IL-6 secretion and endothelial ICAM-1 expression.
    Cheung WY; Simmons CA; You L
    Bone; 2012 Jan; 50(1):104-10. PubMed ID: 21986000
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
    Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
    Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.
    Dezorella N; Pevsner-Fischer M; Deutsch V; Kay S; Baron S; Stern R; Tavor S; Nagler A; Naparstek E; Zipori D; Katz BZ
    Exp Cell Res; 2009 Jul; 315(11):1904-13. PubMed ID: 19328780
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The mechanism of osteoclast differentiation induced by IL-1.
    Kim JH; Jin HM; Kim K; Song I; Youn BU; Matsuo K; Kim N
    J Immunol; 2009 Aug; 183(3):1862-70. PubMed ID: 19587010
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma.
    Abe M; Hiura K; Wilde J; Moriyama K; Hashimoto T; Ozaki S; Wakatsuki S; Kosaka M; Kido S; Inoue D; Matsumoto T
    Blood; 2002 Sep; 100(6):2195-202. PubMed ID: 12200385
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells.
    Pedranzini L; Dechow T; Berishaj M; Comenzo R; Zhou P; Azare J; Bornmann W; Bromberg J
    Cancer Res; 2006 Oct; 66(19):9714-21. PubMed ID: 17018630
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation.
    Xu G; Liu K; Anderson J; Patrene K; Lentzsch S; Roodman GD; Ouyang H
    Blood; 2012 May; 119(18):4205-14. PubMed ID: 22427205
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis.
    Chen H; Li M; Campbell RA; Burkhardt K; Zhu D; Li SG; Lee HJ; Wang C; Zeng Z; Gordon MS; Bonavida B; Berenson JR
    Oncogene; 2006 Oct; 25(49):6520-7. PubMed ID: 16702955
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mitogen-activated protein kinases mediate interleukin-1beta-induced receptor activator of nuclear factor-kappaB ligand expression in human periodontal ligament cells.
    Oikawa A; Kobayashi M; Okamatsu Y; Shinki T; Kamijo R; Yamamoto M; Hasegawa K
    J Periodontal Res; 2007 Aug; 42(4):367-76. PubMed ID: 17559635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.